Abstract
The high risk patient for developing sudden cardiac death is the individual who has underlying structural heart disease and electrical instability manifesting as a ventricular arrhythmia. The event of sudden cardiac death is believed to be due to ventricular fibrillation caused by the development of ventricular tachyarrhythmia in such patients. It is the hope that after initial therapy to the underlying structural heart disease that the successful elimination of ventricular ectopy using antiarrhythmic agents can prevent sudden cardiac death.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morganroth, J., Moore, E. N. (Eds.). The evaluation of new antiarrhytymic drugs. Martinus Nijhoff, Publishers, The Hague, 1981.
Morganroth, J., Michelson, E. L., Horowitz, L. N., et al. Limitations of routine long-term electrocardiographic monitoring to access ventricular ectopic frequency. Circulation, 58: 408, 1978.
Gibson, D., Sawton, E. The use of beta adrenergic receptor blocking drugs in dysrrhythmias. Prof. Cardiovasc. Dis. 12: 16, 1969.
Coltart, D. T., Gibson, D., Shand, D. G. Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br. Med. J. 1: 490, 1971.
Nixon, J. V., Pennington, W., Ritter, W., et al. Efficacy of propranolol in the control of exercise induced or augmented ventricular ectopic activity. Circulation, 57: 115, 1978.
Aronow, W. S., Vyeyama, R. R. Treatment of arrhythmias with intravenous pindolol. Clin. Pharmacol. Ther. 13: 15, 1972.
Winkle, R. A., Lopes, M. G., Goodman, D.J., et al. Propranolol for patients with mitral valve prolapse. Am. Heart J. 93: 422, 1977.
Woosley, R. L., Kornhause, D., Smith, R. et al. Suppression of chronic ventricular arrhythmias with propranolol. Circulation 60: 819, 1979.
Koppes, G. M., Bechmann, C. H., Jones, F.G. Propranolol therapy for ventricular arrhythmias two months post acute myocardial infarction. Am. J. Cardiol. 46: 322, 1980.
Podrid, P.T., Lown, B. Pindolol for ventricular arrhythmias American Heart J. 104: 491, 1982.
Morganroth, J., Moore, E.N. (Eds.). The evaluation of beta blocker and calcium antagonist drugs. Martinus Nijhoff, Publishers, The Hague, 1982, pp. 233 - 245.
Proceedings of the Workshop on: Implications of recent beta blocker trials for post-myocardial infarction patients. National institutes of Health, May, 1982.
Lichstein, E., Morganroth, J., Harrist, R., Hubble, E. Antiarrhythmic effects of beta blockers: preliminary antiarrhythmic data from the Beta Blocker Heart Attack Trial, Circulation, (In press)
Bigger, J. T., Weld, F. M., Rolnitzky, L.M. Prevalence, characteristics and significance of ventricular tachycardia (three or more complexes) detected with ambulatory electro-cardiographic recording in the late hospital phase of acute myocardial infarction. Amer. J. Cardiol. 48: 815, 1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Morganroth, J. (1983). Do Beta Blockers Prevent Sudden Cardiac Death?. In: Morganroth, J., Moore, E.N. (eds) Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment. Developments in Cardiovascular Medicine, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3876-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3876-5_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3878-9
Online ISBN: 978-1-4613-3876-5
eBook Packages: Springer Book Archive